Amitiza gains IBS-C indication

The FDA has approved Amitiza (lubiprostone capsules, from Sucampo and Takeda) for the treatment of irritable bowel syndrome with constipation (IBS-C) in women ≥18 years of age. In two double-blind clinical trials involving 1154 adults, patients receiving Amitiza were nearly twice as likely to achieve a statistically significant overall response compared to those given placebo.

Amitiza is already indicated for the treatment of chronic idiopathic constipation in adults.

For more information call (877) 825-3327 or visit www.amitiza.com.